NCT06854653 2026-02-03
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Prescient Therapeutics, Ltd.
Phase 2 Recruiting
Prescient Therapeutics, Ltd.
M.D. Anderson Cancer Center
Institute of Hematology & Blood Diseases Hospital, China
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Columbia University
Stanford University